7729 Stock Overview
A stem cell research and development company, develops and manufactures novel cellular therapeutics for the treatment of diseases with unmet or under-served medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Steminent Biotherapeutics, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$21.60 |
| 52 Week High | NT$36.65 |
| 52 Week Low | NT$15.25 |
| Beta | 0 |
| 1 Month Change | 11.92% |
| 3 Month Change | -0.23% |
| 1 Year Change | -30.88% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -46.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7729 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 1.6% | -3.2% | 3.8% |
| 1Y | -30.9% | -3.6% | 0.6% |
Return vs Industry: 7729 underperformed the TW Biotechs industry which returned -0.7% over the past year.
Return vs Market: 7729 underperformed the TW Market which returned 0.3% over the past year.
Price Volatility
| 7729 volatility | |
|---|---|
| 7729 Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in TW Market | 10.3% |
| 10% least volatile stocks in TW Market | 4.9% |
Stable Share Price: 7729's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 7729's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | n/a | www.steminent.com |
Steminent Biotherapeutics, Inc., a stem cell research and development company, develops and manufactures novel cellular therapeutics for the treatment of diseases with unmet or under-served medical needs. The company focuses on Stemchymal portfolio of cell therapy research and development programs based on allogeneic stem cells that target neurodegenerative and other degenerative diseases. Its product pipeline includes various pre-clinical and clinical stage therapeutic programs for the treatment of spinocerebellar ataxia (PolyQ SCA), osteoarthritis of the knee, other neurodegenerative diseases, acute liver failure, and post-CPR syndrome.
Steminent Biotherapeutics, Inc Fundamentals Summary
| 7729 fundamental statistics | |
|---|---|
| Market cap | NT$1.21b |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 7729 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7729 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 7729 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 09:03 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Steminent Biotherapeutics, Inc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.